转甲状腺素类淀粉沉积症变性治疗市场－全球产业规模、份额、趋势、机会与预测：按类型、治疗方法、疾病类型、分销管道、地区和竞争格局划分，2021-2031年

全球转甲状腺素类淀粉沉积症治疗市场预计将从 2025 年的 77.8 亿美元大幅成长至 2031 年的 178.2 亿美元，复合年增长率达 14.81%。

该领域包括旨在稳定转甲状腺素蛋白或抑制其在肝臟中生成的药物治疗，从而防止淀粉样蛋白原纤维在心臟和神经组织中积聚。全球人口老化和非侵入性核子医学闪烁显像的广泛应用是推动该领域发展的主要因素，后者显着提高了诊断准确性，优于传统的切片检查技术。例如，欧洲心臟学会报告称，到2025年，约19%的病因不明的肥厚型心肌病老年患者将被诊断为转甲状腺素蛋白淀粉样变性心肌病，这表明标靶筛检正在发现更多患者。

然而，疾病修正治疗的高成本构成了一大障碍，造成了严重的报销难题，并限制了预算紧张的医疗体系获得治疗的机会。这些经济限制导致治疗启动经常被延误，甚至直接被拒付，即使全球确诊病例数量持续成长，也有效地限制了收入成长。

市场驱动因素

全球转甲状腺素类淀粉沉积症治疗市场成长的关键驱动因素是创新疾病修正治疗的引入和日益广泛的应用。医疗专业人员越来越多地使用标靶治疗稳定转甲状腺素蛋白四聚体或抑制其在肝臟中的合成，从而改变疾病的自然进程。现有标准疗法的强劲商业性表现和新产品的快速普及都反映了这一趋势。例如，辉瑞在2024年第三季财报中宣布，其Vyndaqel产品系列的全球销售额达到14.5亿美元，在强劲需求的推动下实现了63%的营业成长。此外，Astra Zeneca在其2024年11月发布的2024年全年及第三季财报中宣布，其新推出的治疗药物Wainua的季度销售额达到2300万美元，表明该药物在神经病变领域获得了良好的早期应用。

强大的临床研发管线和不断增加的研发投入进一步巩固了这一商业性势头，这些投入旨在拓展适应症并提高生存率。製药公司正积极开发新一代RNA干扰和反义寡核苷酸疗法，以治疗传统上难以治疗的心肌病病变患者族群。基因沉默剂治疗心臟疾病的疗效已被证实，相关数据已取得显着进展。 Alnylam Pharmaceuticals公司于2024年6月公布的HELIOS-B III期临床试验结果显示，在ATTR类淀粉沉积症合併心肌病病变患者中，butrisiran可显着降低全因死亡率和復发性心血管事件的综合风险达28%。这些进展对于获得监管部门核准至关重要，预计这将在不久的将来显着扩大市场规模。

市场挑战

转甲状腺素类淀粉沉积症样疾病修正治疗的高昂费用是市场扩张的主要障碍，阻碍了诊断能力提升与产生收入之间的关联。儘管筛检计画能够识别出更多患者，但这些终身治疗的高昂价格迫使公共和私人支付方实施严格的报销通讯协定。这些经济障碍体现在复杂的预先核准程序和拒付上，导致越来越多的确诊患者无法获得治疗。因此，製造商面临日益增长的临床需求，但经济障碍却人为地限制了产品的实际应用。

这种经济差距直接影响患者获得治疗的机会。根据类淀粉沉积症研究联盟（ARCC）2024年的数据，五分之一的转甲状腺素类淀粉沉积症样变性患者表示，由于费用或保险覆盖问题，他们不得不推迟治疗。由于相当一部分患者被迫推迟或中断治疗，经济问题直接缩小了潜在市场规模，并阻碍了该领域的商业性发展。

市场趋势

体内CRISPR-Cas9基因编辑疗法的进展正在从根本上改变市场格局，将治疗模式从慢性管理转变为可能单次给药根治性的方案。与目前需要持续给药的基因沉默剂不同，这些新一代药物利用脂质奈米颗粒永久地惰性肝细胞中的TTR基因，有效阻止致病蛋白的产生。近期公布的持久性数据支持了单次给药即可阻止疾病进展的潜力。例如，Intellia Therapeutics公司于2024年11月公布了临床实验药物Nexigran Dicurmeran的I期临床试验数据，结果显示，无论基准水平如何，该药物在12个月时均能显着且持续地降低所有患者的平均血清TTR水平达90%。

同时，新一代高亲和性TTR稳定剂的商业化正在树立新的疗效标准​​，与以往的疗法相比，其四聚体稳定作用接近完全。这些新型小分子化合物旨在最大限度地提高循环结合率，并显着减少导致心臟淀粉样蛋白沉积的毒性单体的释放。近期监管部门的核准也支持了这种向卓越稳定性发展的趋势。根据BridgeBio Pharma公司2024年11月发布的关于Attruvy获得FDA核准的公告，关键性3期ATTRibute-CM试验的数据显示，与安慰剂相比，Acoramidis在30个月时使全因死亡率和心血管相关再入院的综合风险降低了42%。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球转甲状腺素类淀粉沉积症变性治疗市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 按类型（ATTR-PN、ATTR-CM）
  • 治疗方法（标靶治疗（Onpattro、inotersen、Vyndaqel/Vindamax）、支持治疗和研究治疗方法）
  • 依疾病类型（遗传性转甲状腺素类淀粉沉积症（神经病变、心肌病、混合型）、野生型类淀粉沉积症）
  • 按分销管道（医院药房、专科药房、零售药房、网路药房）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美转甲状腺素类淀粉沉积症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲转甲状腺素类淀粉沉积症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区转甲状腺素类淀粉沉积症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲转甲状腺素类淀粉沉积症样变性治疗市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲转甲状腺素类淀粉沉积症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球转甲状腺素类淀粉沉积症治疗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Alnylam Pharmaceuticals
• Bridgebio Pharma
• Pfizer
• Ionis Pharmaceuticals
• Astrazeneca
• Alexion Pharmaceutical
• Proliferan
• Enobio Pharma
• Moderna
• Intellia Therapeutics
• Regeneron Pharmaceuticals

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Transthyretin Amyloidosis Treatment Market is projected to expand significantly, rising from USD 7.78 Billion in 2025 to USD 17.82 Billion by 2031, reflecting a compound annual growth rate of 14.81%. This sector includes pharmacological treatments aimed at stabilizing the transthyretin protein or inhibiting its production in the liver to stop amyloid fibrils from accumulating in the heart and nerves. Growth is largely fueled by an aging global population and the widespread use of non-invasive nuclear scintigraphy, which has vastly improved diagnostic accuracy over older biopsy techniques. For instance, the European Society of Cardiology noted in 2025 that approximately 19% of elderly patients with unexplained hypertrophic cardiomyopathy were diagnosed with transthyretin amyloid cardiomyopathy, highlighting how targeted screening is revealing a larger patient base.

However, the market faces a major impediment due to the high costs associated with disease-modifying therapies, which create significant reimbursement obstacles and limit access within budget-constrained healthcare systems. These financial limitations frequently lead to delays in starting treatment or outright denial of insurance coverage, effectively curbing revenue growth even as the number of diagnosed cases continues to rise worldwide.

Market Driver

The primary engine for growth in the Global Transthyretin Amyloidosis Treatment Market is the introduction and increasing utilization of innovative disease-modifying therapies. Medical professionals are more frequently prescribing targeted treatments that either stabilize the transthyretin tetramer or suppress its hepatic synthesis, thereby modifying the disease's natural progression. This trend is highlighted by the strong commercial performance of existing standards of care and the rapid uptake of new products. For example, Pfizer Inc. reported in its Third Quarter 2024 Earnings that the Vyndaqel product family reached global revenues of USD 1.45 billion, representing 63 percent operational growth due to high demand. Additionally, AstraZeneca's Year to date and Q3 2024 Results in November 2024 indicated that its newly launched Wainua treatment generated USD 23 million in quarterly revenue, showing strong initial adoption in the polyneuropathy sector.

This commercial momentum is bolstered by a strong clinical pipeline and increased research and development investment aimed at broadening labeled indications and enhancing survival rates. Pharmaceutical companies are actively developing next-generation RNA interference and antisense oligonucleotide therapies to treat the larger cardiomyopathy patient group, which has historically been challenging to manage. A significant breakthrough occurred with the release of data confirming the effectiveness of gene silencers for cardiac issues; according to Alnylam Pharmaceuticals' June 2024 HELIOS-B Phase 3 Study Results, vutrisiran showed a statistically significant 28 percent reduction in the composite risk of all-cause mortality and recurrent cardiovascular events in patients with ATTR amyloidosis and cardiomyopathy. These advancements are essential for regulatory approvals that are expected to substantially expand the market size in the near future.

Market Challenge

A major barrier to market expansion is the exorbitant cost of disease-modifying therapies for transthyretin amyloidosis, which disrupts the link between improved diagnostic capabilities and revenue generation. Although screening programs are successfully identifying more patients, the steep prices of these lifelong medications force public and private insurers to implement strict reimbursement protocols. These financial hurdles often appear as complicated prior authorization processes or coverage refusals, preventing the growing pool of diagnosed patients from accessing treatment. As a result, manufacturers encounter a situation where clinical demand is increasing, yet actual product adoption is artificially constrained by economic gatekeeping.

The disconnect caused by financial toxicity directly affects patient access to care. Data from the Amyloidosis Research Consortium in 2024 revealed that one in five patients with transthyretin amyloidosis reported delaying treatment initiation specifically because of costs or insurance coverage difficulties. With a significant segment of the patient population compelled to postpone or forego therapy, affordability issues are directly shrinking the practical market size and hindering the sector's commercial trajectory.

Market Trends

The market is being fundamentally transformed by the advancement of In Vivo CRISPR-Cas9 gene editing therapeutics, which are shifting the treatment paradigm from chronic management to potential one-time curative solutions. Unlike current gene silencers that require ongoing administration, these next-generation agents use lipid nanoparticles to permanently disable the TTR gene in hepatocytes, effectively stopping the production of disease-causing proteins. The potential for a single dose to halt disease progression is supported by recent durability data; for instance, Intellia Therapeutics announced in its November 2024 Phase 1 Clinical Data that the investigational agent nexiguran ziclumeran achieved a deep and consistent mean serum TTR reduction of 90 percent at month 12 across all patients, irrespective of baseline levels.

Concurrently, the commercialization of next-generation high-affinity TTR stabilizers is setting a new benchmark for efficacy by achieving near-complete tetramer stabilization compared to earlier options. These novel small molecules are designed to maximize blood binding occupancy, thereby significantly lowering the release of toxic monomers responsible for amyloid deposition in the heart. This evolution toward superior stabilization was confirmed by recent regulatory achievements; according to BridgeBio Pharma's November 2024 announcement regarding the FDA approval for Attruby, data from the pivotal Phase 3 ATTRibute-CM trial demonstrated that acoramidis resulted in a 42 percent reduction in the composite risk of all-cause mortality and recurrent cardiovascular-related hospitalizations at month 30 compared to placebo.

Key Market Players

• Alnylam Pharmaceuticals
• Bridgebio Pharma
• Pfizer
• Ionis Pharmaceuticals
• Astrazeneca
• Alexion Pharmaceutical
• Proliferan
• Enobio Pharma
• Moderna
• Intellia Therapeutics
• Regeneron Pharmaceuticals

Report Scope

In this report, the Global Transthyretin Amyloidosis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Transthyretin Amyloidosis Treatment Market, By Type

• ATTR-PN
• ATTR-CM

Transthyretin Amyloidosis Treatment Market, By Therapy

• Targeted Therapy (Onpattro, Inotersen, Vyndaqel/Vyndamax)
• Supportive Therapy
• Pipeline Therapy

Transthyretin Amyloidosis Treatment Market, By Disease Type

• Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed Type)
• Wild Type Amyloidosis

Transthyretin Amyloidosis Treatment Market, By Distribution Channel

• Hospital Pharmacies
• Specialty Pharmacies
• Retail Pharmacies
• Online Pharmacies

Transthyretin Amyloidosis Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Transthyretin Amyloidosis Treatment Market.

Available Customizations:

Global Transthyretin Amyloidosis Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Transthyretin Amyloidosis Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (ATTR-PN, ATTR-CM)
  • 5.2.2. By Therapy (Targeted Therapy (Onpattro, Inotersen, Vyndaqel/Vyndamax), Supportive Therapy, Pipeline Therapy)
  • 5.2.3. By Disease Type (Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed Type), Wild Type Amyloidosis)
  • 5.2.4. By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Transthyretin Amyloidosis Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Therapy
  • 6.2.3. By Disease Type
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Transthyretin Amyloidosis Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Therapy
      • 6.3.1.2.3. By Disease Type
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Canada Transthyretin Amyloidosis Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Therapy
      • 6.3.2.2.3. By Disease Type
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Mexico Transthyretin Amyloidosis Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Therapy
      • 6.3.3.2.3. By Disease Type
      • 6.3.3.2.4. By Distribution Channel

7. Europe Transthyretin Amyloidosis Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Therapy
  • 7.2.3. By Disease Type
  • 7.2.4. By Distribution Channel
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Transthyretin Amyloidosis Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Therapy
      • 7.3.1.2.3. By Disease Type
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. France Transthyretin Amyloidosis Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Therapy
      • 7.3.2.2.3. By Disease Type
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. United Kingdom Transthyretin Amyloidosis Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Therapy
      • 7.3.3.2.3. By Disease Type
      • 7.3.3.2.4. By Distribution Channel
  • 7.3.4. Italy Transthyretin Amyloidosis Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Therapy
      • 7.3.4.2.3. By Disease Type
      • 7.3.4.2.4. By Distribution Channel
  • 7.3.5. Spain Transthyretin Amyloidosis Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Therapy
      • 7.3.5.2.3. By Disease Type
      • 7.3.5.2.4. By Distribution Channel

8. Asia Pacific Transthyretin Amyloidosis Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Therapy
  • 8.2.3. By Disease Type
  • 8.2.4. By Distribution Channel
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Transthyretin Amyloidosis Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Therapy
      • 8.3.1.2.3. By Disease Type
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. India Transthyretin Amyloidosis Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Therapy
      • 8.3.2.2.3. By Disease Type
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Japan Transthyretin Amyloidosis Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Therapy
      • 8.3.3.2.3. By Disease Type
      • 8.3.3.2.4. By Distribution Channel
  • 8.3.4. South Korea Transthyretin Amyloidosis Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Therapy
      • 8.3.4.2.3. By Disease Type
      • 8.3.4.2.4. By Distribution Channel
  • 8.3.5. Australia Transthyretin Amyloidosis Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Therapy
      • 8.3.5.2.3. By Disease Type
      • 8.3.5.2.4. By Distribution Channel

9. Middle East & Africa Transthyretin Amyloidosis Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Therapy
  • 9.2.3. By Disease Type
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Transthyretin Amyloidosis Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Therapy
      • 9.3.1.2.3. By Disease Type
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. UAE Transthyretin Amyloidosis Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Therapy
      • 9.3.2.2.3. By Disease Type
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. South Africa Transthyretin Amyloidosis Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Therapy
      • 9.3.3.2.3. By Disease Type
      • 9.3.3.2.4. By Distribution Channel

10. South America Transthyretin Amyloidosis Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Therapy
  • 10.2.3. By Disease Type
  • 10.2.4. By Distribution Channel
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Transthyretin Amyloidosis Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Therapy
      • 10.3.1.2.3. By Disease Type
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Colombia Transthyretin Amyloidosis Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Therapy
      • 10.3.2.2.3. By Disease Type
      • 10.3.2.2.4. By Distribution Channel
  • 10.3.3. Argentina Transthyretin Amyloidosis Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Therapy
      • 10.3.3.2.3. By Disease Type
      • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Transthyretin Amyloidosis Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Alnylam Pharmaceuticals
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Bridgebio Pharma
• 15.3. Pfizer
• 15.4. Ionis Pharmaceuticals
• 15.5. Astrazeneca
• 15.6. Alexion Pharmaceutical
• 15.7. Proliferan
• 15.8. Enobio Pharma
• 15.9. Moderna
• 15.10. Intellia Therapeutics
• 15.11. Regeneron Pharmaceuticals

16. Strategic Recommendations

17. About Us & Disclaimer